Literature DB >> 22139203

[Kawasaki disease in children and adolescents].

U Neudorf1.   

Abstract

Kawasaki disease (KD) is a systemic vasculitis of unknown etiology. The diagnostic criteria are fulfilled with fever of unknown origin and 4 of the following 5 criteria: bilateral conjunctival injection, cervical lymphadenopathy, polymorphous rash, oral mucous membrane changes (injected lips, strawberry tongue) and peripheral extremity changes (erythema, edema, desquamation). If less than 4 criteria are found incomplete KD can be diagnosed. The therapy is 2 g/kg body weight single dose intravenous immunoglobulin and acetylsalicylic acid (ASS). In the long-term follow-up the main focus is on the coronary arteries because coronary changes play a key role in the intensity of long-term management. There is some evidence that KD is a risk factor for cardiovascular diseases in adults.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22139203     DOI: 10.1007/s00393-011-0801-y

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  19 in total

1.  Rising incidence of Kawasaki disease in England: analysis of hospital admission data.

Authors:  Anthony Harnden; Bernadette Alves; Aziz Sheikh
Journal:  BMJ       Date:  2002-06-15

2.  Rotational ablation and stent placement for severe calcific coronary artery stenosis after Kawasaki disease.

Authors:  Thomas F Peters; Sanjay R Parikh; Cass A Pinkerton
Journal:  Catheter Cardiovasc Interv       Date:  2002-08       Impact factor: 2.692

3.  Incidence of Kawasaki disease in Japan: the nationwide surveys of 1999-2002.

Authors:  Hiroshi Yanagawa; Yosikazu Nakamura; Mayumi Yashiro; Ritei Uehara; Izumi Oki; Kazunori Kayaba
Journal:  Pediatr Int       Date:  2006-08       Impact factor: 1.524

4.  Valvular heart disease in Kawasaki syndrome: incidence and natural history.

Authors:  T Akagi; H Kato; O Inoue; N Sato; K Imamura
Journal:  Am Heart J       Date:  1990-08       Impact factor: 4.749

5.  Late intravenous gamma globulin treatment in infants and children with Kawasaki disease and coronary artery abnormalities.

Authors:  M Marasini; G Pongiglione; D Gazzolo; A Campelli; D Ribaldone; S Caponnetto
Journal:  Am J Cardiol       Date:  1991-09-15       Impact factor: 2.778

6.  Hospitalizations for Kawasaki disease among children in the United States, 1988-1997.

Authors:  Ruey-Kang R Chang
Journal:  Pediatrics       Date:  2002-06       Impact factor: 7.124

7.  Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association.

Authors:  Jane W Newburger; Masato Takahashi; Michael A Gerber; Michael H Gewitz; Lloyd Y Tani; Jane C Burns; Stanford T Shulman; Ann F Bolger; Patricia Ferrieri; Robert S Baltimore; Walter R Wilson; Larry M Baddour; Matthew E Levison; Thomas J Pallasch; Donald A Falace; Kathryn A Taubert
Journal:  Pediatrics       Date:  2004-12       Impact factor: 7.124

8.  Kawasaki syndrome hospitalizations in the United States, 1997 and 2000.

Authors:  Robert C Holman; Aaron T Curns; Ermias D Belay; Claudia A Steiner; Lawrence B Schonberger
Journal:  Pediatrics       Date:  2003-09       Impact factor: 7.124

9.  Novel and traditional cardiovascular risk factors in children after Kawasaki disease: implications for premature atherosclerosis.

Authors:  Yiu-fai Cheung; Tak-cheung Yung; Sidney C F Tam; Marco H K Ho; Adolphus K T Chau
Journal:  J Am Coll Cardiol       Date:  2004-01-07       Impact factor: 24.094

10.  Cardiac biopsy of Kawasaki disease.

Authors:  C Yutani; S Go; T Kamiya; O Hirose; H Misawa; H Maeda; T Kozuka; S Onishi
Journal:  Arch Pathol Lab Med       Date:  1981-09       Impact factor: 5.534

View more
  1 in total

1.  Kawasaki disease in children: Epidemiology, clinical symptoms and diagnostics of 231 cases in 10 years.

Authors:  Hua Zhu; Shao-Fei Yu; Yu-Xin Bai; Yan-Yan Liang; Xue-Wen Su; Jing-Ying Pan
Journal:  Exp Ther Med       Date:  2015-05-11       Impact factor: 2.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.